Related Experiment Videos
Intervention therapy for coronary artery disease in the elderly
Insights
Elderly patients with acute myocardial infarction benefit from thrombolytic intervention, with age no longer a barrier. Percutaneous coronary angioplasty (PTCA) also shows promise for elderly patients with coronary artery disease (CAD).
Area of Science:
- Cardiology
- Geriatric Medicine
- Interventional Cardiology
Background:
- Coronary artery disease (CAD) management in the elderly presents unique challenges.
- Traditional age cutoffs for intervention therapy may exclude eligible older adults.
- Assessing individual physiological status is crucial for elderly patients with CAD.
Purpose of the Study:
- To review the application and efficacy of intervention therapies for coronary artery disease (CAD) in the elderly.
- To determine appropriate eligibility criteria for thrombolytic intervention in older adults with acute myocardial infarction (AMI).
- To evaluate the role of percutaneous coronary angioplasty (PTCA) in elderly patients with various manifestations of CAD.
Main Methods:
- Systematic review of existing data on intervention therapy for CAD in the elderly population.
- Analysis of eligibility criteria for thrombolytic therapy in acute myocardial infarction (AMI) patients.
- Examination of outcomes for percutaneous coronary angioplasty (PTCA) in elderly individuals with stable and unstable angina.
Main Results:
- Age 70 or 75 is no longer an appropriate upper limit for thrombolytic intervention in acute myocardial infarction (AMI); physiologically active elderly patients without contraindications should be considered eligible.
- Thrombolytic intervention for eligible elderly patients with ST-segment elevation myocardial infarction (STEMI) is recommended due to increased lives saved compared to younger patients.
- Elderly patients, particularly those with comorbidities limiting coronary artery bypass grafting (CABG), appear to tolerate and benefit from percutaneous coronary angioplasty (PTCA).
Conclusions:
- Thrombolytic intervention should be recommended for most eligible elderly patients presenting with acute myocardial infarction (AMI), especially those with ST-elevation.
- Further controlled trials are needed to refine dosing and assess bleeding risks in the elderly for thrombolytic therapy.
- Individualized assessment is key for applying intervention therapies, including PTCA, to elderly patients with coronary artery disease (CAD) to maximize benefits.
Abstract:
The central aim of this review was to examine the application of intervention therapy for CAD in the elderly population. The data reviewed indicates that it is no longer appropriate to use age 70 or 75 as the upper limit of eligibility for thrombolytic intervention in patients with acute myocardial infarction. Elderly who are physiologically active without contraindications to thrombolytic therapy should be considered eligible. Additional controlled trials specifically targeted at the elderly population are needed to better define the precise dosing regimen and the magnitude and extent of bleeding complications in this group. Nevertheless, it appears appropriate to recommend thrombolytic intervention for most eligible elderly patients presenting with acute myocardial infarction. This recommendation is based on the fact that the higher mortality in the elderly results in more lives saved per patient treated than for younger patients. It is important to reemphasize that this recommendation is for treating elderly patients with acute infarction as suggested by ST-segment elevation and/or Q waves, without contraindications to thrombolytic therapy. Those with non-Q-wave infarctions, hypertension, recent stroke, history of bleeding, or other contraindications are not candidates. Regarding intervention therapy in other elderly patients with acute and chronic manifestations of coronary disease, results also appear very encouraging. Elderly patients appearing to tolerate PTCA include those with all forms of angina from chronic stable angina to unstable angina. Although only observational data are on hand at present, our review suggests these elderly patients tolerate PTCA well and indeed may benefit. The elderly patients who have co-morbid factors that adversely influence the application of CABG for revascularization may be the best candidates for PTCA. At present, the challenge for the physician is to carefully assess each elderly patient on an individual basis for intervention therapy. This evaluation should be aimed at identifying factors that may permit application of intervention treatment to the elderly patients who are most likely to receive the greatest benefit.